Vermilion Energy Inc (VET) Announces $0.23 Monthly Dividend

Vermilion Energy Inc (TSE:VET) (NYSE:VET) announced a monthly dividend on Wednesday, February 27th, TickerTech reports. Shareholders of record on Friday, March 15th will be paid a dividend of 0.23 per share on Friday, March 15th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 8.29%. The ex-dividend date is Wednesday, February 27th.

Shares of TSE:VET traded down C$0.02 on Tuesday, reaching C$33.29. 939,529 shares of the company’s stock were exchanged, compared to its average volume of 825,244. The stock has a market capitalization of $5.03 billion and a price-to-earnings ratio of -102.43. Vermilion Energy has a fifty-two week low of C$26.67 and a fifty-two week high of C$49.67. The company has a debt-to-equity ratio of 73.75, a quick ratio of 0.43 and a current ratio of 0.52.

Get Vermilion Energy alerts:

In other news, Director Catherine L. Williams acquired 2,000 shares of the company’s stock in a transaction that occurred on Thursday, December 13th. The shares were acquired at an average price of C$30.40 per share, with a total value of C$60,800.00. Also, Senior Officer Mona Jean Jasinski acquired 2,830 shares of the company’s stock in a transaction that occurred on Monday, January 28th. The stock was purchased at an average cost of C$31.13 per share, for a total transaction of C$88,108.65. Following the acquisition, the insider now owns 33,771 shares in the company, valued at C$1,051,419.56.

A number of analysts recently weighed in on the stock. Canaccord Genuity dropped their price objective on shares of Vermilion Energy from C$55.00 to C$43.00 in a report on Thursday, January 10th. National Bank Financial dropped their price objective on shares of Vermilion Energy from C$58.00 to C$41.00 and set an “outperform” rating on the stock in a report on Monday, December 10th. Finally, Raymond James raised shares of Vermilion Energy from an “outperform” rating to a “strong-buy” rating and set a C$51.00 price objective on the stock in a report on Wednesday, November 14th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of C$53.17.

COPYRIGHT VIOLATION WARNING: “Vermilion Energy Inc (VET) Announces $0.23 Monthly Dividend” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4181672/vermilion-energy-inc-vet-announces-0-23-monthly-dividend.html.

Vermilion Energy Company Profile

Vermilion Energy Inc acquires, explores, develops, and produces crude petroleum and natural gas. As of December 31, 2017, it owned 74% interest in 330,900 net acres of developed land and 87% interest in 376,400 net acres of undeveloped land, as well as 375 net producing natural gas wells and 475 net producing oil wells in Canada; and 96% interest in 208,900 net acres of developed land and 99% interest in 379,800 net acres of undeveloped land in the Aquitaine and Paris Basins, as well as 332 net producing oil wells and 3 net producing gas wells in France.

Featured Story: Fundamental Analysis – How It Helps Investors

Heska (HSKA) Scheduled to Post Earnings on Tuesday

Heska (NASDAQ:HSKA) is scheduled to be announcing its earnings results before the market opens on Tuesday, February 26th. Analysts expect the company to announce earnings of $0.75 per share for the quarter.

NASDAQ HSKA opened at $98.56 on Monday. The stock has a market cap of $747.99 million, a price-to-earnings ratio of 47.61 and a beta of 0.91. Heska has a fifty-two week low of $57.15 and a fifty-two week high of $114.50.

Get Heska alerts:

In other Heska news, Director G Irwin Gordon sold 4,000 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $102.00, for a total value of $408,000.00. Following the transaction, the director now directly owns 25,074 shares of the company’s stock, valued at approximately $2,557,548. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin S. Wilson sold 1,631 shares of the stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $104.00, for a total transaction of $169,624.00. The disclosure for this sale can be found here. Insiders sold a total of 36,141 shares of company stock valued at $3,547,787 over the last quarter. 15.90% of the stock is currently owned by company insiders.

Several equities analysts recently issued reports on HSKA shares. Zacks Investment Research upgraded Heska from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a research note on Thursday, January 10th. Canaccord Genuity reissued a “buy” rating and issued a $118.00 target price on shares of Heska in a report on Wednesday, February 20th. Finally, BidaskClub downgraded Heska from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $110.50.

TRADEMARK VIOLATION NOTICE: “Heska (HSKA) Scheduled to Post Earnings on Tuesday” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/4177338/heska-hska-scheduled-to-post-earnings-on-tuesday.html.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Featured Article: What is the quiet period?

$0.06 EPS Expected for Enphase Energy Inc (ENPH) This Quarter

Equities analysts expect that Enphase Energy Inc (NASDAQ:ENPH) will announce earnings per share of $0.06 for the current quarter, Zacks reports. Five analysts have issued estimates for Enphase Energy’s earnings. The highest EPS estimate is $0.07 and the lowest is $0.05. Enphase Energy reported earnings of $0.01 per share in the same quarter last year, which would indicate a positive year over year growth rate of 500%. The firm is expected to announce its next earnings report after the market closes on Tuesday, February 26th.

On average, analysts expect that Enphase Energy will report full year earnings of $0.11 per share for the current year, with EPS estimates ranging from $0.09 to $0.12. For the next year, analysts forecast that the business will report earnings of $0.28 per share, with EPS estimates ranging from $0.20 to $0.33. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Enphase Energy.

Get Enphase Energy alerts:

Several research firms recently weighed in on ENPH. Cowen reiterated an “in-line” rating and set a $8.50 price objective (up previously from $6.75) on shares of Enphase Energy in a research note on Thursday. BidaskClub lowered shares of Enphase Energy from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. ValuEngine upgraded shares of Enphase Energy from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. HC Wainwright set a $9.00 price objective on shares of Enphase Energy and gave the stock a “buy” rating in a research note on Tuesday, January 29th. Finally, TheStreet upgraded shares of Enphase Energy from a “d+” rating to a “c-” rating in a research note on Wednesday, November 28th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $7.57.

Several large investors have recently made changes to their positions in the business. Westside Investment Management Inc. increased its stake in shares of Enphase Energy by 28.4% in the fourth quarter. Westside Investment Management Inc. now owns 8,986 shares of the semiconductor company’s stock valued at $43,000 after purchasing an additional 1,986 shares during the period. Northern Trust Corp increased its stake in shares of Enphase Energy by 0.3% in the fourth quarter. Northern Trust Corp now owns 930,434 shares of the semiconductor company’s stock valued at $4,402,000 after purchasing an additional 2,423 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in shares of Enphase Energy by 24.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 12,605 shares of the semiconductor company’s stock valued at $60,000 after purchasing an additional 2,500 shares during the period. Two Sigma Advisers LP increased its stake in shares of Enphase Energy by 0.6% in the fourth quarter. Two Sigma Advisers LP now owns 418,709 shares of the semiconductor company’s stock valued at $1,980,000 after purchasing an additional 2,500 shares during the period. Finally, CoreCommodity Management LLC increased its stake in shares of Enphase Energy by 27.2% in the fourth quarter. CoreCommodity Management LLC now owns 24,381 shares of the semiconductor company’s stock valued at $115,000 after purchasing an additional 5,214 shares during the period. Institutional investors own 39.74% of the company’s stock.

ENPH traded up $0.15 on Thursday, hitting $7.38. 76,111 shares of the company’s stock were exchanged, compared to its average volume of 1,708,329. The firm has a market cap of $768.69 million, a price-to-earnings ratio of -13.67 and a beta of 1.39. Enphase Energy has a twelve month low of $2.37 and a twelve month high of $7.94. The company has a quick ratio of 1.42, a current ratio of 1.55 and a debt-to-equity ratio of 21.18.

Enphase Energy Company Profile

Enphase Energy, Inc, together with its subsidiaries, designs, develops, and sells microinverter systems for residential and commercial markets in the United States and internationally. The company's semiconductor-based microinverter system converts direct current (DC) electricity to alternating current (AC) electricity at the individual solar module level.

Featured Article: What is the yield curve?

Get a free copy of the Zacks research report on Enphase Energy (ENPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Energy Stocks To Buy Right Now

tags:CLF,MPC,CVRR,RRC,SUN,

It's no coincidence that stocks sold off in the beginning of February, right as the market's level of confidence about the Federal Reserve's upcoming rate increases has grown. The inflation outlook and the outlook for stronger economic growth taken together do point to several rate increases this year.

The latest FOMC minutes revealed that Fed officials are now positive on the economic outlook, with some having "marked up their forecasts for economic growth in the near term relative to those made for the December meeting." Translation: More rate hikes this year. If interest rates rise, they will take a further toll on bonds' market prices down the road.

---Sponsored Link--- America's Secret Weapon In The Oil War
A tech revolution is taking place under the radar. And only a few investors know about it. Scientists have found a way to produce clean oil for only $23 per barrel and this tech breakthrough could lead the U.S. to energy independence.And one small company is at the center of it all... Get the story here.

The good news is that these rate hikes are conditional on further economic growth. Stronger growth is generally good for stocks, whose valuations depend on the outlook for future earnings. This is why I think higher rates won't necessarily spell doom for equities. With growing profits and higher dividends a distinct possibility, dividend-paying stocks offer the potential for both income and capital gains.

Top 5 Energy Stocks To Buy Right Now: Cliffs Natural Resources Inc.(CLF)

Advisors' Opinion:

• [By Ethan Ryder]

  An issue of Cleveland-Cliffs Inc (NYSE:CLF) bonds fell 1.1% as a percentage of their face value during trading on Wednesday. The high-yield issue of debt has a 5.75% coupon and will mature on March 1, 2025. The debt is now trading at $95.44 and was trading at $97.00 one week ago. Price changes in a company’s bonds in credit markets often anticipate parallel changes in its stock price.

• [By Tyler Crowe]

  For years, iron ore producer Cleveland-Cliffs (NYSE:CLF) has been in the midst of a turnaround plan that has completely transformed the company from a debt-laden business suffering from di-worsification to a much leaner miner focused solely on serving North American steel mills. At times, it looked like a company on the brink of bankruptcy, but those days are behind it, as it has produced some impressive earnings results lately.

• [By Tyler Crowe]

  At first glance, Cleveland-Cliffs' (NYSE:CLF) most recent earnings report might make shareholders want to push the sell button as fast as they can open their brokerage accounts. But before you  precipitously sour on this iron miner, take a deeper look at its results. Even though its revenue and earnings were down drastically, those declines were largely a product of its moves to shut down unprofitable assets. 

Top 5 Energy Stocks To Buy Right Now: Marathon Petroleum Corporation(MPC)

Advisors' Opinion:

• [By Jason Hall, Tyler Crowe, and John Bromels]

  If you're shopping for great buys in the oil patch right now, three Motley Fool contributors think you should take a close look at tech-heavy but asset-light oilfield services provider Core Laboratories N.V. (NYSE:CLB), value-priced independent oil producer Apache Corporation (NYSE:APA), and refining giant Marathon Petroleum Corp (NYSE:MPC). 

• [By Tyler Crowe, Matthew DiLallo, and Reuben Gregg Brewer]

  Fortunately for those looking at these attractive valuations, oil's end-of-days scenario is likely a ways down the road. So we asked three Fool.com contributors to highlight a stock they see in the oil industry right now that looks attractive. Here's why they picked Plains All American Pipeline (NYSE:PAA), Marathon Petroleum (NYSE:MPC), and Magellan Midstream Partners (NYSE:MMP). 

• [By Tyler Crowe]

  Ever since Marathon Petroleum's (NYSE:MPC) IPO back in 2012, the company has gone from being a mid-sized independent oil refiner with some retail holdings to becoming the nation's largest refiner with an extensive network of retail stations and two large logistics subsidiaries. This past quarter was the culmination of that work, as the company completed the acquisition of Andeavor -- formerly Tesoro, Western Refining, and Northern Tier Refining. Based on the most recent results, investors should be pleased that management decided to do this deal.

• [By Matthew DiLallo]

  On top of that, MPLX's parent company, oil refiner Marathon Petroleum (NYSE:MPC), announced that it plans to acquire fellow refiner Andeavor (NYSE:ANDV), which owns not only some midstream assets but MLP Andeavor Logistics (NYSE:ANDX). While Marathon currently plans to operate Andeavor Logistics as a stand-alone entity, it makes sense to eventually merge that company into MPLX. If that happens, it would further enhance MPLX's income stream and growth prospects, increasing the likelihood that the company can continue boosting its 7.1%-yielding payout each quarter.

Top 5 Energy Stocks To Buy Right Now: CVR Refining, LP(CVRR)

Advisors' Opinion:

• [By Logan Wallace]

  CVR Refining LP (NYSE:CVRR) declared a quarterly dividend on Wednesday, July 25th, NASDAQ reports. Stockholders of record on Monday, August 6th will be given a dividend of 0.66 per share by the oil and gas company on Monday, August 13th. This represents a $2.64 annualized dividend and a dividend yield of 12.25%. The ex-dividend date of this dividend is Friday, August 3rd. This is a positive change from CVR Refining’s previous quarterly dividend of $0.51.

• [By Dan Caplinger]

  Finally, shares of CVR Energy fell 9%. The holding company agreed to exchange its stock to investors in related entity CVR Refining (NYSE:CVRR), accepting as many as 37.1 million units at a ratio of 0.6335 shares of CVR Energy for every unit of CVR Refining exchanged. In a release, CVR Energy said that "many CVR Refining unitholders may wish to hold their investment in the form of common stock rather than partnership interests" after recent tax reform legislation. But it's unclear why CVR Energy would make an offer at a 25% premium rather than simply having CVR Refining convert to a corporate entity or use similar steps that wouldn't adversely affect CVR Energy shareholders for the benefit of CVR Refining unitholders. CVR Refining finished the session 8% higher.

• [By Lisa Levin] Gainers Acacia Communications, Inc. (NASDAQ: ACIA) shares rose 18.3 percent to $37.25 in pre-market trading after gaining 1.74 percent on Friday. Kitov Pharma Ltd (NASDAQ: KTOV) rose 12.1 percent to $2.69 in pre-market trading after surging 4.80 percent on Friday. NXP Semiconductors N.V. (NASDAQ: NXPI) rose 10.9 percent to $109.75 in pre-market trading after Bloomberg reported that the China’s Commerce Ministry has restarted its review of QUALCOMM Incorporated’s (NASDAQ: QCOM) proposed takeover of NXP Semiconductors. Renewable Energy Group, Inc. (NASDAQ: REGI) rose 10.6 percent to $15.20 in pre-market trading. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15. NeoPhotonics Corporation (NYSE: NPTN) rose 10 percent to $6.40 in pre-market trading. Vaxart, Inc. (NASDAQ: VXRT) shares rose 8 percent to $5.54 in pre-market trading after gaining 2.19 percent on Friday. Profire Energy, Inc. (NASDAQ: PFIE) rose 7.3 percent to $4.58 in pre-market trading after gaining 6.22 percent on Friday. Marvell Technology Group Ltd. (NASDAQ: MRVL) rose 7 percent to $22.49 in pre-market trading after falling 1.96 percent on Friday. Oclaro, Inc. (NASDAQ: OCLR) shares rose 6.9 percent to $9.16 in pre-market trading. TransEnterix, Inc. (NYSE: TRXC) rose 5.7 percent to $2.24 in pre-market trading after gaining 3.92 percent on Friday. CVR Refining, LP (NYSE: CVRR) rose 5.4 percent to $19.70 in pre-market trading. Federal Agricultural Mortgage Corporation (NYSE: AGM) rose 5.2 percent to $92.95 in pre-market trading. International Game Technology PLC (NYSE: IGT) rose 5.2 percent to $29.94 in pre-market trading. Lumentum Holdings Inc. (NASDAQ: LITE) shares rose 5.1 percent to $66.30 in the pre-market trading session. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 5 percent to $10.70 in pre-market trading after climbing 15.66 percent on Friday. Finisar
• [By ]

  The Big Boys' Pick
  Of the group, CVRR (NYSE: CVRR) is in the best position. Apparently, Mr. Icahn agrees, which is why he owns 5.7 million shares, a stake worth more than $100 million. Other big institutional owners include the likes of Goldman Sachs, Morgan Stanley and JP Morgan.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on CVR Refining (CVRR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Energy Stocks To Buy Right Now: Range Resources Corporation(RRC)

Advisors' Opinion:

• [By Chris Lange]

  The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Range Resources Corp. (NYSE: RRC) which rose about 6% to $16.05. The stock's 52-week range is $11.93 to $25.96. Volume was 8.6 million compared to the daily average volume of 7.4 million.

• [By Tyler Crowe]

  Companies in this region have had more measured growth plans because of the lack of pipelines. As Miller mentioned, though, improved efficiency has resulted in most companies outpacing their production growth plans. The lack of takeaway capacity has led to much lower prices for in-basin production. Range Resources (NYSE:RRC), one of the larger producers in the region, has noted that its price realizations were 10% below benchmark prices because of a lack of takeaway capacity. 

• [By Paul Ausick]

  Range Resources Corp. (NYSE: RRC) fell about 4.4% Tuesday to post a new 52-week low of $14.43 after closing at $15.09 on Monday. The 52-week high is $34.93. Volume of about 15 million was nearly double the daily average of around 7.7 million shares traded. The company had no specific news.

• [By Paul Ausick]

  Range Resources Corp. (NYSE: RRC) fell about 3.6% Monday to post a new 52-week low of $14.77 after closing at $15.30 on Friday. The 52-week high is $35.64. Volume of about 9.4 million was about 20% higher than the daily average of around 7.7 million shares traded. The company had no specific news.

• [By Joseph Griffin]

  Media headlines about Range Resources (NYSE:RRC) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Range Resources earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the oil and gas exploration company an impact score of 46.3371462950661 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Range Resources (RRC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Energy Stocks To Buy Right Now: Sunoco LP(SUN)

Advisors' Opinion:

• [By ]

  That's the case for Sunoco (NYSE: SUN). After posting a net loss of $0.09 per share in 2017, the gas station owner is expected to swing to a hefty profit of $2.35 per share in 2018. But of the 14 analysts who follow the company, earnings estimates range as low as $1.22 and as high as $3.35 -- so there is a high degree of uncertainty. 

• [By Tyler Crowe]

  Around this time last year, Sunoco LP (NYSE:SUN) announced a transformative divestment. The sale of its extensive retail filling station network to convenience store specialist 7-Eleven was going to give management the cash it needed to clean up its balance sheet and provide it with a much more stable revenue source. One would have assumed that when the company made this transaction, Wall Street would reward the stock with a higher valuation. That hasn't been the case, though, as Sunoco's stock is still languishing with a sky-high distribution yield north of 12%.

• [By Benzinga News Desk]

  President Donald Trump hinted he may intervene in the Justice Department’s Russia investigation, as a Senate panel advanced a measure to protect Special Counsel Robert Mueller: Link

  ECONOMIC DATA USA GDP (QoQ) for Q1 2.30% vs 2.00% Est; Prior 2.90% The University of Michigan's consumer confidence index for April is schedule for release at 10:00 a.m. ET. The Baker Hughes North American rig count report for the latest week will be released at 1:00 p.m. ET. Data on farm prices for the recent week will be released at 3:00 p.m. ET. ANALYST RATINGS Stifel upgraded Facebook (NASDAQ: FB) from Hold to Buy Morgan Stanley upgraded Acacia Communications (NASDAQ: ACIA) from Underweight to Equal-Weight Jefferies downgraded Sunoco (NYSE: SUN) from Hold to Underperform KBW downgraded Oaktree Capital (NYSE: OAK) from Outperform to Market Perform

  This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

Top 5 Performing Stocks To Watch Right Now

tags:KOP,MPLX,JVA,JKS,ANTX,

Despite the recent uptick in volatility across the market due to ongoing trade wars and rising interest rates, some top fund managers still think that growth stocks will continue to produce strong returns on capital for investors this year and beyond. Unfortunately, there isn't exactly a surfeit of attractively priced growth equities at the moment thanks to the aging bull market.

That's why I think growth investors may need to look toward somewhat riskier areas -- such as clinical-stage biotech companies -- to find the most compelling growth opportunities in this heated market. Clinical-stage biotechs, after all, have consistently been some of the best-performing stocks for the bulk of the past eight years, and the rapid pace of innovation in the space strongly suggests that this favorable trend isn't about to evaporate overnight.  

Image source: Getty Images.

Top 5 Performing Stocks To Watch Right Now: Koppers Holdings Inc.(KOP)

Advisors' Opinion:

• [By Stephan Byrd]

  Koppers (NYSE:KOP) was upgraded by equities research analysts at TheStreet from a “c” rating to a “b-” rating in a report released on Friday.

• [By Logan Wallace]

  Mackay Shields LLC reduced its holdings in shares of Koppers Holdings Inc. (NYSE:KOP) by 61.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,786 shares of the specialty chemicals company’s stock after selling 36,800 shares during the period. Mackay Shields LLC owned about 0.11% of Koppers worth $874,000 at the end of the most recent reporting period.

• [By Logan Wallace]

  Koppers (NYSE:KOP) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Top 5 Performing Stocks To Watch Right Now: MPLX LP(MPLX)

Advisors' Opinion:

• [By Tyler Crowe]

  So in this spirit, I thought I would share with you a stock you may want to consider for your own portfolio because it is one I have recently purchased myself: oil and gas logistics player MPLX LP (NYSE:MPLX). Here's why I think it is a company worthy of investment and the recent change to the business that compelled me to buy this stock. 

• [By Matthew DiLallo]

  The best dividend growth stocks are those that give their investors a raise year in and year out. However, some companies aim even higher by providing their investors with increases every quarter. Two of these dividend dynamos are Magellan Midstream Partners (NYSE:MMP) and MPLX (NYSE:MPLX), which both should have plenty of fuel to continue increasing their payouts each quarter for at least the next few years. 

• [By Tyler Crowe, Matthew DiLallo, and Reuben Gregg Brewer]

  So we asked three of our Motley Fool contributors to sift through stocks in the oil industry to come up with three that investors should put on their radars. Here's why they picked MPLX LP (NYSE:MPLX), Cimarex Energy (NYSE:XEC), and ExxonMobil (NYSE:XOM).

• [By Matthew DiLallo]

  The project could also be an important one to facilitate another pipeline that's under development. Targa Resources (NYSE:TRGP), MPLX (NYSE: MPLX), NextEra Energy, and private equity-backed WhiteWater Midstream recently announced that they're working on the Whistler Pipeline project, which would also move 2 Bcf/d from Waha to the Gulf Coast. The partners have already locked up gas supplies from a variety of sources, including from gas processing plants operated by Targa Resources as well as from the 1.4 Bcf/D Agua Blanca Pipeline, which is owned by a joint venture between Targa, MPLX, WPX Energy, and WhiteWater. However, the Whistler Pipeline's developers still need about 500,000 MMcf/d of additional volume commitments to fill its capacity, which could come from producers shipping on Double E.

• [By Matthew DiLallo]

  That's why those who like dividends will undoubtedly love what Enterprise Products Partners (NYSE:EPD), Magellan Midstream Partners (NYSE:MMP), and MPLX (NYSE:MPLX) have to offer. Not only does this trio of energy midstream master limited partnerships (MLPs) pay well-above-average dividends that currently have yields of between 5.6% and 7.2%, but they have consistently increased their payment rate each quarter. With those payouts on rock-solid ground and more growth in the forecast, this trio of MLPs is perfect for dividend fans.

• [By Logan Wallace]

  COPYRIGHT VIOLATION NOTICE: “Mplx (MPLX) Receives New Coverage from Analysts at Deutsche Bank” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3371782/mplx-mplx-receives-new-coverage-from-analysts-at-deutsche-bank.html.

Top 5 Performing Stocks To Watch Right Now: Coffee Holding Co., Inc.(JVA)

Advisors' Opinion:

• [By Max Byerly]

  Coffee (NASDAQ:JVA) posted its earnings results on Friday. The company reported $0.00 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.07), MarketWatch Earnings reports. Coffee had a return on equity of 3.99% and a net margin of 1.23%. The firm had revenue of $23.44 million during the quarter.

Top 5 Performing Stocks To Watch Right Now: JinkoSolar Holding Company Limited(JKS)

Advisors' Opinion:

• [By Max Byerly]

  These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

  Get JinkoSolar alerts: JinkoSolar Holding Co., Ltd. (JKS) stock closes Yesterday with $12.12 (nasdaqfortune.com) Roth Capital Downgrades JinkoSolar Holding Co., Ltd. (JKS) to Sell Citing Negative China Outlook (streetinsider.com) Review the Facts about stock: JinkoSolar Holding Co., Ltd. (JKS) (connectinginvestor.com) Featured Stock: Jinkosolar Holding Company Ltd (JKS) (emnnews.com)

  Several research firms recently commented on JKS. Zacks Investment Research lowered shares of JinkoSolar from a “hold” rating to a “sell” rating in a research note on Thursday, June 7th. Credit Suisse Group reduced their price objective on shares of JinkoSolar from $22.00 to $13.00 and set a “neutral” rating for the company in a research note on Thursday, June 7th. UBS Group began coverage on shares of JinkoSolar in a research note on Friday, March 16th. They set a “buy” rating and a $26.00 price objective for the company. Roth Capital set a $19.00 price objective on shares of JinkoSolar and gave the stock a “hold” rating in a research note on Tuesday, March 27th. Finally, Goldman Sachs Group lowered shares of JinkoSolar to a “sell” rating in a research note on Wednesday, June 6th. Seven research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company’s stock. JinkoSolar has an average rating of “Sell” and an average price target of $16.17.

• [By Travis Hoium]

  The impact will have ripple effects across the industry. Major manufacturers like Canadian Solar (NASDAQ:CSIQ), JinkoSolar (NYSE:JKS), Hanwha Q Cells (NASDAQ:HQCL), and JA Solar (NASDAQ:JASO) will see margins squeezed as volume and sales prices fall. They were all enjoying higher margins and strong demand in early 2018, so the could reverse to net losses later this year. 

• [By Travis Hoium]

  Solar stocks took a beating Monday after China cut its national incentives to install solar projects. Shares of solar panel manufacturers Canadian Solar Inc. (NASDAQ:CSIQ) fell as much as 14.5%, JinkoSolar Holding Co. (NYSE:JKS) dropped as much as 17%, and Daqo New Energy Corp (NYSE:DQ) fell as much as 31.3% while inverter manufacturer Enphase Energy Inc (NASDAQ:ENPH) fell up to 13.5%. By early afternoon, most major stocks in the solar industry were down double digits.

• [By Travis Hoium]

  Solar stocks have been on a downward march for most of the year. First Solar (NASDAQ:FSLR), SunPower Corporation (NASDAQ:SPWR), JinkoSolar (NYSE:JKS), and Canadian Solar (NASDAQ:CSIQ) are all down double digits, and there are no clear signs of a turnaround in sight. 

Top 5 Performing Stocks To Watch Right Now: Anthem, Inc.(ANTX)

Advisors' Opinion:

• [By Max Byerly]

  Antimatter (CURRENCY:ANTX) traded 10.9% lower against the US dollar during the twenty-four hour period ending at 19:00 PM E.T. on June 10th. One Antimatter coin can now be purchased for approximately $0.0001 or 0.00000002 BTC on exchanges. During the last seven days, Antimatter has traded 12.5% lower against the US dollar. Antimatter has a market cap of $0.00 and $7.00 worth of Antimatter was traded on exchanges in the last 24 hours.

• [By Logan Wallace]

  Antimatter (CURRENCY:ANTX) traded flat against the U.S. dollar during the one day period ending at 12:00 PM E.T. on July 22nd. In the last seven days, Antimatter has traded up 17.8% against the U.S. dollar. Antimatter has a total market capitalization of $0.00 and $1.00 worth of Antimatter was traded on exchanges in the last 24 hours. One Antimatter coin can currently be bought for $0.0001 or 0.00000001 BTC on popular cryptocurrency exchanges.

Ranking The Top 3 High Yield Mutual Funds

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1125630129&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1125630129/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g;

If you&a;rsquo;re worried that stocks are expensive &l;i&g;again&l;/i&g;, well, they are. The current bull market is making a run at history. But it&a;rsquo;s &l;i&g;also&l;/i&g; costly to stay in cash (and lock in &l;i&g;zero&l;/i&g; income). Fortunately, it&a;rsquo;s possible to buy some downside protection &l;i&g;with&l;/i&g; yield.

I understand the &a;ldquo;I&a;rsquo;m worried so I&a;rsquo;m sitting in cash&a;rdquo; concern. And I know many investors who continue to sit on their money and hope for a big pullback. But wouldn&a;rsquo;t it be nicer to bank 32% total returns with 8%, 9% or even 10% or more of it coming as dividends?

Our &l;i&g;Contrarian Income Report&l;/i&g; subscribers who smartly stayed with &l;b&g;Omega Healthcare Investors &l;/b&g;&a;ndash; a big paying REIT &a;ndash; have done much better than their scared cash hoarder friends, as well as the broader market in general. Last year actually started inauspiciously as OHI announced a dividend &a;ldquo;freeze.&a;rdquo; The stock slipped. But a freeze isn&a;rsquo;t the same as a cut &a;ndash; and OHI&a;rsquo;s payout was well covered by its funds from operations (&a;ldquo;FFO&a;rdquo; &a;ndash; more on why this matters shortly).

The misunderstanding would soon be our gain, as the stock yielded 10% (thanks to years of previous dividend hikes). And anytime that OHI has paid double-digits in the past, it marked a major bottom for the stock. So why would this time be any different?

Let&a;rsquo;s &a;ldquo;zoom in&a;rdquo; to see how OHI rallied off its most recent double-digit high to return 32% including dividends!

Secure yields are the truly the &a;ldquo;rubber duckies&a;rdquo; of the investing world. Mr. Market can push them underwater for a period of time, but eventually, they rocket up to the surface.

With that in mind, let&a;rsquo;s &a;ldquo;zig&a;rdquo; a zagging stock market by discussing three high paying mutual funds. Big dividends plus a human at the wheel &a;ndash; that&a;rsquo;s my idea of a bear-proof payout-powered portfolio.

&l;b&g;Vanguard Real Estate Index&l;/b&g;

&l;b&g;Type: &l;/b&g;REIT (real estate investment trusts)

&l;b&g;Assets Under Management:&l;/b&g; $59 billion

&l;b&g;Yield:&l;/b&g; 4.2%

&l;b&g;Expenses:&l;/b&g; 0.12%

At a yield of just more than 4%, the &l;b&g;Vanguard Real Estate Index&l;/b&g; &a;ndash; which has a twin fund, the &l;b&g;Vanguard Real Estate ETF &l;/b&g;&a;ndash; isn&a;rsquo;t knocking the socks off high-income investors. But VGSLX actually is one of the best-yielding equity mutual funds in the game.

In fact, most of the top mutual funds for equity income are invested in real estate investment trusts (REITs). No surprise there. REITs are naturally income-friendly thanks to their mandate to redistribute 90% or more of their taxable income back to you and me as dividends. Better still, REITs were shackled in 2018, &l;a href=&q;https://contrarianoutlook.com/5-reits-to-double-your-income-in-2019/&q; target=&q;_blank&q;&g;helping to drive up yields to their highest point in roughly a decade&l;/a&g;!

Vanguard&a;rsquo;s indexed REIT fund is weighted by market cap, so the fund is filled with blue chips such as communications-infrastructure play &l;b&g;American Tower&l;/b&g;, mall operator &l;b&g;Simon Property Group&l;/b&g; and logistics REIT &l;b&g;Prologis&l;/b&g;.

It&a;rsquo;s a worthy fund that has served its shareholders well since inception in 2001, and it does allow investors to keep almost all of their returns with a cheap expense ratio. That said, if you&a;rsquo;re looking to bundle REITs together in a fund, this is one area where active management tends to shine. In fact, &l;a href=&q;https://contrarianoutlook.com/2-top-dividend-funds-8-yields-to-buy-now/&q; target=&q;_blank&q;&g;several CEFs yield far more than VGSLX&l;/a&g; and have bested Vanguard&a;rsquo;s offering over the long-term.

Let&a;rsquo;s move on.

&l;b&g;AB High Income&l;/b&g;

&l;b&g;Type: &l;/b&g;High-Yield Bond

&l;b&g;Assets Under Management:&l;/b&g; $5.9 billion

&l;b&g;Yield:&l;/b&g; 7.6%

&l;b&g;Expenses:&l;/b&g; 0.82%*

Next up is a no-brainer in the high-yield field: junk bonds.

You can get plenty of yield out of just the American junk market, but &l;b&g;AB High Income &l;/b&g;takes things a step farther by breaking out its passport and delving into developed-market and emerging-market bonds, too.

AGDAX actually invests in more than just junk debt. High-yield corporates make up 44% of the fund, with another 10% in collateralized mortgage obligations, 9% in investment-grade corporates, 9% in emerging-market sovereign debt, 6% in &a;ldquo;global governments&a;rdquo; and the rest peppered among other types of income investments.

Unlike with the indexed VGSLX, AllianceBernstein&a;rsquo;s fund has plenty of managerial brainpower to go around. Its five-manager team averages nearly 26 years of experience apiece, including 21 years apiece at AB.

But boy, is it costly. The 0.82% in annual fees isn&a;rsquo;t all that bad &a;ndash; you&a;rsquo;ll typically find that in CEFs &a;ndash; but what you won&a;rsquo;t find is an additional 4.25% sales charge that AB charges for these A shares. That will cost you &l;i&g;literally thousands if not tens of thousands of dollars&l;/i&g; over the course of your investment.

&l;b&g;Templeton Emerging Markets Bond&l;/b&g;

&l;b&g;Type: &l;/b&g;Emerging-Markets Bond

&l;b&g;Assets Under Management:&l;/b&g; $35.2 million

&l;b&g;Yield:&l;/b&g; 8.6%

&l;b&g;Expenses:&l;/b&g; 1.17%*

Emerging-market bonds are one of the highest-yielding assets you can invest in. The inherent enhanced risk of less developed countries &a;ndash; complete with higher levels of corruption, geopolitical risk and less regulated markets &a;ndash; forces sky-high yields to compensate investors for their trouble.

In the case of &l;b&g;Templeton Emerging Markets Bond&l;/b&g;, you&a;rsquo;re getting well north of 8% for that trouble, but you&a;rsquo;re also actually putting a cap on your risk. See, FEMGX &a;ndash; under the managing team of Michael Hasenstab, Calvin Ho and Laura Burakreis &a;ndash; holds 124 different positions across a number of EMs, such as Brazil, Argentina, Ghana, Indonesia and Thailand.

Management typically wants to invest 80% of the portfolio in EM bonds, but they can use their discretion should opportunity dry up. In fact, at the moment, less than 60% of the portfolio is invested in bonds, with the rest parked in cash.

But those managerial decisions will cost you &a;ndash; in fact, even more than AGDAX.

FEMGX charges a steep 4.25% maximum sales charge, as well as 1.17% in annual expenses. But it doesn&a;rsquo;t stop there. There&a;rsquo;s also a potential 0.75% CDSC (deferred sales charge), and a 0.25% 12b-1 fee (marketing!) to swallow.

Worse &a;hellip;

Management certainly earns its fees at times, but it&a;rsquo;s hard-pressed to keep up with its own litany of charges.

Disclosure: none

&l;/p&g;

Store Closures Coming in 2019, but Don't Call It a Retail Apocalypse

Just because it's cold today does not mean that global warming isn't real. Weather isn't climate and a chilly day (or even an unexpectedly cold season) does not mean much in the big-picture science behind climate change.

The same can be said for the predictions of retail apocalypse you see everywhere. Stores are closing -- and a new report from Coresight forecasts that number to grow year-over-year -- but blaming those closures on the rise in digital sales ignores what's actually happening (and some basic math).

Digital retailers have exposed how poorly many brick-and-mortar chains are run, forcing a number of them to close stores or even go bankrupt. That's not happening because consumers have chosen digital over physical. Instead, shoppers have more choice and they can now more easily opt out of shopping at brick-and-mortar chains that do a bad job.

Just because some stores are closing does not mean that there is a retail apocalypse. Image source: Getty Images.

Take a look at which chains have closed

Retailers that have embraced the current market dynamics like Best Buy (NYSE: BBY), Target, and Walmart have thrived. These chains acknowledged that digital rivals changed the game. Best Buy, which was at one time at risk of being driven out of business by Amazon, changed its business in numerous ways (none of which included significant store closures).

The electronics retailer made its stores into destinations by adding store-within-a-store shops for major brands and focusing on growing its service business. It also adjusted its prices because consumers might pay a little more for an HDMI cable to have it now, but they won't pay two or three times what Amazon charges, even if that means waiting two days for it.

In addition, Best Buy, along with the other successful retailers mentioned above have embraced omnichannel retailing and they use their stores as a major part of fulfillment. A Best Buy customer might buy online and pickup in store or buy online and return in a store. The company might also fulfill a digital order from a store. To make the logistics of all this work has taken significant investment.

Best Buy made that investment and it's thriving while its not-so-dearly departed rival Radio Shack still operated as if the internet did not exist. That's something you could accuse many other "retail apocalypse" victims of doing, including Sears, J.C. Penney, Sports Authority, and so many others.

A look at the numbers

Store closures actually fell in 2018 when 5,524 stores were shuttered compared to the previous year when the lights went out at 8,139, according to Coresight. In 2019, Coresight said 2,187 stores have already been closed, up 23% compared to the same time period last year. That figure was released before reports came out Thursday that Payless ShoeSource is planning to close its 2,300 stores when it files for a second bankruptcy later this month.

Since 2017 e-commerce sales as a percentage of all retail sales have climbed from 9% to 10% in 2018 with a forecast of them growing to 11.1% in 2019 and 13.7% by 2021, according to a Statista chart. That growth does impact brick-and-mortar chains, but it's also coming at a time when the National Retail Federation (NRF) reported that U.S. retail sales overall (including digital and brick-and-mortar) grew by 4.6% in 2018 and are expected to grow between 3.8%-4.4% this year.

That's a lot of numbers to say that while digital sales are growing as a percentage of the whole, the whole is growing as well. Using the NRF projections, overall sales will grow from $3.48 trillion in 2018 to between $3.82 trillion and $3.84 trillion in 2019 (a 9.8% to 10.3% rise). Digital sales will go from $682.8 billion in 2018 to between $751.1 billion and $764.8 billion (a 10% to 12% rise). That means that brick-and-mortar sales will go from roughly $2.79 trillion in 2018 to about $3 trillion in 2019 (using the top of the NRF range), which is a 7.5% rise.

Those numbers don't factor in that brick-and-mortar locations -- at least at well-run chains like Best Buy -- help facilitate digital sales. A need remains for physical retailers. Demand, while it's not growing as fast it is on the digital side, will continue to increase. It's not a retail apocalypse. It's a culling of weak, poorly run retailers which did not embrace the changing needs of consumers.

 

Zynga Inc (ZNGA) Receives Average Recommendation of “Buy” from Analysts

Zynga Inc (NASDAQ:ZNGA) has been assigned a consensus recommendation of “Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $4.98.

Several analysts have weighed in on the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $6.00 target price on shares of Zynga in a report on Thursday, February 7th. Goldman Sachs Group assumed coverage on Zynga in a report on Wednesday, January 30th. They issued a “buy” rating and a $5.30 target price on the stock. Stephens assumed coverage on Zynga in a report on Thursday, January 10th. They issued an “equal weight” rating and a $4.75 target price on the stock. BidaskClub raised Zynga from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 5th. Finally, Barclays set a $4.00 target price on Zynga and gave the company a “sell” rating in a report on Sunday, December 30th.

Get Zynga alerts:

In other news, Director Ellen F. Siminoff sold 12,000 shares of the company’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $3.52, for a total value of $42,240.00. Following the sale, the director now directly owns 191,812 shares in the company, valued at $675,178.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Jeffrey Buckley sold 100,000 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $4.00, for a total value of $400,000.00. Following the completion of the sale, the chief accounting officer now owns 36,808 shares in the company, valued at $147,232. The disclosure for this sale can be found here. Insiders sold 434,694 shares of company stock worth $1,749,063 over the last 90 days. Company insiders own 11.87% of the company’s stock.

Large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Zynga by 1.7% during the third quarter. Vanguard Group Inc. now owns 65,906,089 shares of the company’s stock worth $264,283,000 after buying an additional 1,082,874 shares during the period. First Hawaiian Bank lifted its position in Zynga by 18.5% during the fourth quarter. First Hawaiian Bank now owns 18,240 shares of the company’s stock worth $72,000 after buying an additional 2,845 shares during the period. Vanguard Group Inc lifted its position in Zynga by 1.7% during the third quarter. Vanguard Group Inc now owns 65,906,089 shares of the company’s stock worth $264,283,000 after buying an additional 1,082,874 shares during the period. Assenagon Asset Management S.A. purchased a new position in Zynga during the fourth quarter worth about $9,389,000. Finally, FMR LLC purchased a new position in Zynga during the second quarter worth about $1,927,000. Institutional investors and hedge funds own 79.03% of the company’s stock.

Zynga stock traded up $0.05 during trading hours on Friday, hitting $5.03. The stock had a trading volume of 25,931,889 shares, compared to its average volume of 15,086,064. The firm has a market capitalization of $4.34 billion, a price-to-earnings ratio of 251.50, a price-to-earnings-growth ratio of 1.65 and a beta of 0.43. Zynga has a 1-year low of $3.32 and a 1-year high of $5.14.

Zynga (NASDAQ:ZNGA) last posted its earnings results on Wednesday, February 6th. The company reported $0.02 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.02). The firm had revenue of $248.69 million during the quarter, compared to analyst estimates of $245.78 million. Zynga had a net margin of 1.70% and a return on equity of 1.14%. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the company posted $0.01 EPS. On average, equities research analysts anticipate that Zynga will post 0.13 earnings per share for the current fiscal year.

About Zynga

Zynga Inc develops, markets, and operates social games as live services in the United States and internationally. The company's games are played on mobile platforms, such as iOS and Android operating systems, as well as on social networking sites, including Facebook. It also provides advertising services comprising mobile and display ads, engagement ads and offers, and branded virtual goods and sponsorships to advertising agencies and brokers; and software licensing and maintenance services related to NaturalMotion technology, as well as licenses its own brands.

Recommended Story: Relative Strength Index

Top 5 Biotech Stocks To Invest In Right Now

tags:BIIB,AMGN,ARQL,ALNY, LISTEN TO ARTICLE 6:04 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

A New York congressman and his son were indicted for insider trading related to the shares of an Australian biotechnology firm, federal prosecutors in Manhattan said on Wednesday.

Christopher Collins, a Republican Congressman representing the 27th District of New York, his son Cameron Collins, and Stephen Zarsky, the father of Cameron Collins’s fiancée, were charged by federal prosecutors in Manhattan. Prosecutors believe it to be the first insider-trading case against a sitting congressman.

Top 5 Biotech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By George Budwell]

  Biotech heavyweight Biogen (NASDAQ:BIIB) has now lost over 13% of its value so far this year. To be fair, this year hasn't been kind to biotechs in general, thanks to President Trump's aggressive trade policies with China. But Biogen's value has been declining at a far faster rate than the industry as a whole due to stiffer competition in the all-important multiple sclerosis (MS) space.

• [By Chris Lange]

  The S&P 500 stock posting the largest daily percentage gain ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded up about 19% at $355.17. The stock's 52-week range is $249.17 to $370.57. Volume was over 12 million compared to the daily average volume of 1.6 million.

• [By Cory Renauer]

  Biogen Inc.'s (NASDAQ:BIIB) Alzheimer's disease hopeful topped the list last year, but repeated failures with experimental drugs that attack the disease from a similar angle have all flopped. Despite the risk, EvaluatePharma estimates aducanumab's present value at around $8.4 billion and this figure will rise or fall dramatically when the company reads off results of ongoing pivotal trials, probably in early 2020.

• [By Brian Orelli]

  Data source: Ionis Pharmaceuticals.

  What happened with Ionis Pharmaceuticals this quarter? Revenue increased thanks to $41 million in royalties from Biogen's (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis' financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.

  Image source: Getty Images.

Top 5 Biotech Stocks To Invest In Right Now: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By ]

  Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.

• [By Keith Speights]

  It's not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.

• [By Jon C. Ogg]

  In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.

• [By Logan Wallace]

  AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

• [By Joseph Griffin]

  South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.

Top 5 Biotech Stocks To Invest In Right Now: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL)’s share price rose 6.2% during trading on Thursday . The stock traded as high as $5.21 and last traded at $5.15. Approximately 955,706 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 1,244,948 shares. The stock had previously closed at $4.85.

• [By Cory Renauer]

  What's behind these dramatic gains? Read on to find out.

  Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

  Data source: YCharts.

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on ArQule (ARQL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Maxx Chatsko]

  Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

Top 5 Biotech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Jim Crumly]

  You would think that when a drug company that's been working for 16 years to develop drugs using a novel therapeutic approach wins its first-ever approval from the U.S. Food and Drug Administration (FDA), confetti would fall from the ceiling and its investors would be celebrating a huge stock gain the next day. That didn't happen this week for shareholders of Alnylam Pharmaceuticals (NASDAQ:ALNY), with shares dropping 6.6% the day after the announcement, and there were two main reasons for that.

• [By Shane Hupp]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now.  However,  In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release.”

• [By Cory Renauer]

  If approved, Tegsedi will run directly into competition with Alnylam's (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven't been tested in a head-to-head study, but most analysts expect Alnylam's drug to gain a much larger share of the limited space than Akcea's.

• [By Todd Campbell]

  Spark Therapeutics (NASDAQ:ONCE) reported its hemophilia A drug significantly reduced bleeding events and the need for prophylactic factor VIII infusions, but investors sold shares on worry that the gene therapy's safety could be a problem. Investors similarly headed for the exits with Rite Aid (NYSE:RAD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) after the former scuttled an attempt to sell itself and the latter secured a first-in-class FDA approval. Are these falling stocks worth buying?

The Post-Earnings Drop of Coca-Cola Stock Is a Buying Opportunity

Coca-Cola (NYSE:KO) stock dropped sharply yesterday after the consumer-staples giant reported fourth-quarter numbers that were largely in-line with expectations. But KO also issued cautious guidance for fiscal 2019 which seemed to incorporate slowing global economic trends and persistent foreign-exchange headwinds, causing KO stock to decline from $50 to $45.

KO stock was trading right near its all-time highs heading into the Q4 print. But its results were pretty good, as its organic sales rose 5% and its operating profits rose 11%.

In that context, the decline of Coca-Cola stock looks like a buying opportunity. Everything is still going well for KO. The company is continuing to pivot from a soda-focused brand to a multi-beverage brand that is much more relevant to today’s health-conscious consumers. That transition is powering consistent, healthy revenue growth.

Meanwhile, KO has exercised disciplined cost control, pushing its margins higher. The result of these trends is healthy, steady revenue and profit growth.

This healthy, steady top-line and bottom-line growth will ultimately power Coca-Cola stock higher. KO stock was trading at a premium valuation heading into the print, supported by unreasonably high expectations. Now expectations are lower, and Coca-Cola stock is cheaper. Thus, now is the right time to buy KO stock.

Q4 Numbers Were Good, But Not Great

Coca-Cola’s Q4 numbers were good. But they weren’t great or anything special. Instead, they were more of the same stable revenue and profit growth that this company has reported over the past several quarters and years.

Thus, in the big picture, Coca-Cola’s top-line growth trajectory has largely stabilized around 4%, excluding acquisitions. The problem was that, when KO stock was around $50, some investors were hoping that 5% and up sales growth was the new norm. That isn’t the case. Fiscal 2018 was just an unusually good year. Next year (and likely for the foreseeable future), organic sales growth  (i.e. excluding the impact of acquisitions) will be in the 3%-5% range.

Compare Brokers

Meanwhile, excluding currency fluctuations, operating income rose 8% in the quarter, and 11% on a trailing-twelve-month basis. That is fairly consistent with what KO has reported over the past several quarters. This low double-digit percentage-operating-profit-growth-trajectory is projected to persist, too, as KO expects its operating profits to rise 10%-11% in 2019.

Overall, KO’s fourth-quarter numbers and its 2019 guidance underscore that Coca-Cola’s growth outlook is stable, but largely below the company’s 2018 results. That disappointed some investors who had bought KO stock last year.

Coca-Cola’s Long-Term Outlook Is Healthy

In the big picture, the long-term fundamentals of Coca-Cola remain healthy. All the post-earnings drop did was make Coca-Cola stock cheaper while showing that KO’s fundamentals remain strong. Consequently, this dip of Coca-Cola stock is a buying opportunity.

Coca-Cola has made a big shift over the past several years, transforming from a soda-focused brand with declining popularity and relevance to a multi-beverage brand with climbing popularity and relevance. As part of this transition, the company has added new iterations like Zero to the core Coca-Cola product lineup, while broadening the product portfolio to include a wide range of teas, coffees, sparkling drinks, and enhanced waters that resonate with today’s health-conscious consumers.

This pivot is working. It’s driving consistent, steady mid-single-digit, organic sales growth. In tandem with management’s cost control measures, the transformation is driving high-single digit percentage to low-double-digit-percentage operating-profit growth.

None of the company’s fundamentals has changed in the wake of its Q4 results. The company’s organic revenues are expected to rise 4% in fiscal 2019, while its operating profits are expected to rise just over 10%.

The only thing that has changed is the valuation of Coca-Cola stock. Heading into the print, KO stock was trading at nearly 23 times analysts’ forward earnings estimate with a sub-3.2% dividend yield. Relative to historical standards, that’s a big P/E multiple and a low yield for KO stock.

Now, though, the valuation of Coca-Cola stock is much more “normal”. Its forward multiple is back around 20, which is roughly in-line with its average valuation over the last five years. The dividend yield has risen to 3.4%, above the average yield of KO stock over the last five years. Meanwhile, KO is still poised to deliver mid-single-digit-organic sales growth and grow its operating profit by about 10%.

As a result, the decline of Coca-Cola stock is a buying opportunity. KO’s fundamentals remain largely unchanged, while KO stock just went from slightly overvalued to slightly undervalued.

The Bottom Line on Coca-Cola Stock

In the big picture, Coca-Cola has a found a winning strategy: Acquiring relevant, popular brands, and distributing them around the globe. As long as this strategy continues to power mid-single-digit organic sales growth and operating-profit growth of about 10%, KO stock should be bought on dips.

As of this writing, Luke Lango was lo

Cornell Pochily Investment Advisors Inc. Increases Stake in Vanguard Dividend Appreciation ETF (VIG)

Cornell Pochily Investment Advisors Inc. increased its position in shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) by 18.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,525 shares of the company’s stock after buying an additional 1,958 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Vanguard Dividend Appreciation ETF were worth $1,226,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Hilltop Holdings Inc. boosted its holdings in Vanguard Dividend Appreciation ETF by 140.2% in the third quarter. Hilltop Holdings Inc. now owns 38,071 shares of the company’s stock worth $4,214,000 after acquiring an additional 22,219 shares in the last quarter. Gemmer Asset Management LLC boosted its holdings in Vanguard Dividend Appreciation ETF by 68.2% in the fourth quarter. Gemmer Asset Management LLC now owns 1,314 shares of the company’s stock worth $129,000 after acquiring an additional 533 shares in the last quarter. Signaturefd LLC boosted its holdings in Vanguard Dividend Appreciation ETF by 49.2% in the third quarter. Signaturefd LLC now owns 547,257 shares of the company’s stock worth $60,581,000 after acquiring an additional 180,571 shares in the last quarter. Planning Directions Inc. boosted its holdings in Vanguard Dividend Appreciation ETF by 4.1% in the fourth quarter. Planning Directions Inc. now owns 33,532 shares of the company’s stock worth $3,284,000 after acquiring an additional 1,334 shares in the last quarter. Finally, Legacy Private Trust Co. boosted its holdings in Vanguard Dividend Appreciation ETF by 54.9% in the fourth quarter. Legacy Private Trust Co. now owns 4,878 shares of the company’s stock worth $478,000 after acquiring an additional 1,728 shares in the last quarter.

Get Vanguard Dividend Appreciation ETF alerts:

Vanguard Dividend Appreciation ETF stock opened at $106.79 on Wednesday. Vanguard Dividend Appreciation ETF has a 52 week low of $91.68 and a 52 week high of $112.61.

WARNING: “Cornell Pochily Investment Advisors Inc. Increases Stake in Vanguard Dividend Appreciation ETF (VIG)” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4147979/cornell-pochily-investment-advisors-inc-increases-stake-in-vanguard-dividend-appreciation-etf-vig.html.

Vanguard Dividend Appreciation ETF Profile

Vanguard Dividend Appreciation ETF (the Fund) seeks to track the investment performance of the Dividend Achievers Select Index. Vanguard Dividend Appreciation ETF is an exchange-traded share class of Vanguard Dividend Appreciation Index Fund. The Fund will hold all the stocks in the index in approximately the same proportions as their weightings in the index.

Featured Article: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding VIG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanguard Dividend Appreciation ETF (NYSEARCA:VIG).

Best Medical Stocks To Own Right Now

tags:STAA,NOAH,CDK,SSBI,MOD,MTCH,

Fibrocell Science (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm presently has a $2.00 price target on the stock. Zacks Investment Research‘s price objective points to a potential upside of 6.38% from the stock’s previous close.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Best Medical Stocks To Own Right Now: STAAR Surgical Company(STAA)

Advisors' Opinion:

• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday. Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each. Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55. Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months. Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75. STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results. Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday. China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday. YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings. MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings. Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share. Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701. Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings. The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings. Ca
• [By Lisa Levin]

  STAAR Surgical Company (NASDAQ: STAA) shares shot up 26 percent to $21.03 after reporting upbeat Q1 results.

  Shares of Integrated Media Technology Limited (NASDAQ: IMTE) got a boost, shooting up 56 percent to $34.2425. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.

• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 73.3 percent to $3.90. Integrated Media Technology Limited (NASDAQ: IMTE) shares gained 51 percent to $33.1365. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months. Monaker Group, Inc. (NASDAQ: MKGI) shares jumped 34 percent to $3.00. Sharing Economy International Inc. (NASDAQ: SEII) shares rose 28.2 percent to $4.51 after gaining 9.32 percent on Wednesday. STAAR Surgical Company (NASDAQ: STAA) shares jumped 27.8 percent to $21.40 after reporting upbeat Q1 results. Boxlight Corporation (NASDAQ: BOXL) rose 20.5 percent to $8.920 after climbing 107.87 percent on Wednesday. Xspand Products Lab Inc (NASDAQ: XSPL) gained 19.5 percent to $ 5.97. Xspand Products priced its IPO at $5 per share. YRC Worldwide Inc. (NASDAQ: YRCW) rose 18.9 percent to $10.035 following upbeat quarterly earnings. ENDRA Life Sciences Inc. (NASDAQ: NDRA) gained 18.3 percent to $3.0177. ENDRA Life Sciences is expected to report Q1 results on May 15. MYR Group Inc. (NASDAQ: MYRG) rose 18.1 percent to $35.85 after the company posted strong Q1 earnings. Rudolph Technologies, Inc. (NASDAQ: RTEC) shares jumped 16 percent to $30.75 following upbeat quarterly earnings. TTM Technologies, Inc. (NASDAQ: TTMI) gained 13.7 percent to $16.53 after reporting Q1 results. Insight Enterprises, Inc. (NASDAQ: NSIT) shares surged 12 percent to $40.06 following better-than-expected Q1 earnings. TreeHouse Foods, Inc. (NYSE: THS) rose 11.8 percent to $40.93 following Q1 results. Engility Holdings, Inc. (NYSE: EGL) surged 11.2 percent to $27.36. Engility reported upbeat quarterly earnings. Synalloy Corporation (NASDAQ: SYNL) rose 10.7 percent to $19.10 following Q1 results. Logitech International S.A. (NASDAQ: LOGI)
• [By Joseph Griffin]

  STAAR Surgical (NASDAQ:STAA) was upgraded by equities researchers at TheStreet from a “c” rating to a “b-” rating in a research report issued on Monday.

• [By Keith Speights]

  Three big healthcare winners this week were STAAR Surgical (NASDAQ:STAA), Tenet Healthcare (NYSE:THC), and Portola Pharmaceuticals (NASDAQ:PTLA). Each of these stocks jumped more than 24% over the last few days. Are STAAR Surgical, Tenet, and Portola smart picks for investors after the stocks' huge gains?

• [By Keith Speights]

  Shares of STAAR Surgical Company (NASDAQ:STAA) were up 21.5% as of 11:25 a.m. EDT on Thursday. The big jump occurred after the maker of implantable lenses announced its second-quarter earnings results on Wednesday evening.

Best Medical Stocks To Own Right Now: Noah Holdings Ltd.(NOAH)

Advisors' Opinion:

• [By Max Byerly]

  Noah Holdings (NYSE:NOAH)’s share price hit a new 52-week high and low on Monday . The stock traded as low as $57.81 and last traded at $57.76, with a volume of 191661 shares traded. The stock had previously closed at $54.50.

• [By Max Byerly]

  Noah (NYSE:NOAH) was downgraded by analysts at Nomura from a buy rating to a neutral rating.

  TherapeuticsMD (NASDAQ:TXMD) was given a $12.00 price target by analysts at Oppenheimer Holdings Inc.. The firm currently has a buy rating on the stock.

• [By Ethan Ryder]

  Noah Coin (CURRENCY:NOAH) traded down 3.6% against the U.S. dollar during the 24-hour period ending at 21:00 PM Eastern on July 1st. In the last week, Noah Coin has traded up 15% against the U.S. dollar. One Noah Coin token can currently be purchased for about $0.0041 or 0.00000065 BTC on major exchanges. Noah Coin has a total market capitalization of $0.00 and approximately $375,126.00 worth of Noah Coin was traded on exchanges in the last day.

• [By Stephan Byrd]

  Noah Coin (CURRENCY:NOAH) traded down 0.2% against the US dollar during the 24-hour period ending at 10:00 AM Eastern on May 14th. Noah Coin has a market capitalization of $0.00 and approximately $2.39 million worth of Noah Coin was traded on exchanges in the last day. One Noah Coin token can currently be purchased for approximately $0.0083 or 0.00000095 BTC on cryptocurrency exchanges. Over the last seven days, Noah Coin has traded down 8.5% against the US dollar.

• [By Max Byerly]

  Noah Coin (CURRENCY:NOAH) traded 3.3% higher against the US dollar during the twenty-four hour period ending at 20:00 PM Eastern on February 3rd. During the last seven days, Noah Coin has traded 10% lower against the US dollar. Noah Coin has a total market cap of $6.11 million and approximately $75,297.00 worth of Noah Coin was traded on exchanges in the last 24 hours. One Noah Coin token can now be purchased for $0.0002 or 0.00000005 BTC on popular cryptocurrency exchanges including YoBit, DDEX, Mercatox and Livecoin.

• [By Shane Hupp]

  Noah (NYSE: NOAH) and MAN Grp PLC/ADR (OTCMKTS:MNGPY) are both mid-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Best Medical Stocks To Own Right Now: CDK Global, Inc.(CDK)

Advisors' Opinion:

• [By Motley Fool Transcribers]

  CDK Global Inc  (NASDAQ:CDK)Q2 2019 Earnings Conference CallFeb. 05, 2019, 8:30 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Max Byerly]

  CDK Global Inc (NASDAQ:CDK) shares hit a new 52-week low during trading on Wednesday after Morgan Stanley lowered their price target on the stock from $75.00 to $68.00. Morgan Stanley currently has an equal weight rating on the stock. CDK Global traded as low as $59.84 and last traded at $60.56, with a volume of 54440 shares changing hands. The stock had previously closed at $60.77.

• [By Stephan Byrd]

  Traders bought shares of CDK Global Inc (NASDAQ:CDK) on weakness during trading on Thursday. $24.87 million flowed into the stock on the tick-up and $8.74 million flowed out of the stock on the tick-down, for a money net flow of $16.13 million into the stock. Of all companies tracked, CDK Global had the 12th highest net in-flow for the day. CDK Global traded down ($0.31) for the day and closed at $62.85

Best Medical Stocks To Own Right Now: Summit State Bank(SSBI)

Advisors' Opinion:

• [By Max Byerly]

  ValuEngine upgraded shares of Summit State Bank (NASDAQ:SSBI) from a hold rating to a buy rating in a research note released on Saturday.

  Separately, TheStreet raised Summit State Bank from a c+ rating to a b rating in a report on Wednesday, February 14th.

Best Medical Stocks To Own Right Now: Modine Manufacturing Company(MOD)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Modine Manufacturing (MOD)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Modum (CURRENCY:MOD) traded 1% higher against the U.S. dollar during the 24-hour period ending at 23:00 PM ET on May 7th. One Modum token can currently be purchased for $3.01 or 0.00031911 BTC on cryptocurrency exchanges including Kucoin, IDEX, Binance and Mercatox. Over the last seven days, Modum has traded 9% higher against the U.S. dollar. Modum has a total market cap of $55.00 million and $789,835.00 worth of Modum was traded on exchanges in the last 24 hours.

• [By Motley Fool Transcribers]

  Modine Manufacturing Co  (NYSE:MOD)Q3 2019 Earnings Conference CallFeb. 01, 2019, 9:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Lisa Levin] Gainers Comstock Holding Companies, Inc. (NASDAQ: CHCI) shares surged 115.8 percent to $4.3591. Comstock reported conversion of the majority of its unsecured, short-term debt into non-convertible preferred equity. Stellar Biotechnologies, Inc. (NASDAQ: SBOT) jumped 38.2 percent to $3.0251 after the company disclosed that it achieved robust viral clearance for its manufacturing process. Universal Corporation (NYSE: UVV) surged 26.7 percent to $61.40 after reporting fiscal Q4 results. Hudson Technologies Inc. (NASDAQ: HDSN) rose 18.9 percent to $2.58. Evolus, Inc. (NASDAQ: EOLS) shares gained 17.8 percent to $22.8009. The Cato Corporation (NYSE: CATO) shares gained 17.5 percent to $21.07 after the company posted better-than-expected first-quarter results. Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.9 percent to $3.3613. Destination Maternity Corporation (NASDAQ: DEST) shares gained 15.5 percent to $3.35 after the board announced late Wednesday the election of four activist-backed director nominees. Three women and one man comprise the selected group championed by NGM Capital’s Nathan Miller and Kenosis Capital’s Peter O’Malley. Destination Maternity had advocated for another slate of three men and interim CEO Melissa Payner-Gregor. The new directors are Holly Alden, Marla Ryan, Anne-Charlotte Windal and Christopher Morgan. AXT, Inc. (NASDAQ: AXTI) rose 15 percent to $7.65. nLIGHT, Inc. (NASDAQ: LASR) gained 14.5 percent to $34.27 following Q1 results. Achieve Life Sciences, Inc. (NASDAQ: ACHV) rose 14.3 percent to $11.4303. Bilibili Inc.. (NASDAQ: BILI) shares climbed 13.9 percent to $14.16 after announcing Q1 results. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) gained 13.2 percent to $2.91 after an amended 13D filing from Steel Partners Holdings shows a raised stake in the company from 6.99 million shares to 29.98 million shares, or a 17.8 percent stake. HUYA Inc. (NYSE: HUYA) gained 13.1

Best Medical Stocks To Own Right Now: Match Group, Inc.(MTCH)

Advisors' Opinion:

• [By Chris Lange]

  Match Group Inc. (NASDAQ: MTCH) saw its short interest decrease to 25.06 million from the previous 25.52 million. Shares were trading at $49.54, in a 52-week range of $18.11 to $49.98.

• [By Jeremy Bowman]

  One possible acquisition could be Match Group (NASDAQ:MTCH), the parent of Tinder and a leader in the online dating industry, whose valuation has ballooned to $16 billion. Facebook said earlier this year it would launch its own dating product, but taking over Match would be an easier way to assert its power in the industry. The two businesses have a natural overlap, and Facebook's advertising acumen could benefit the company's ad-based products. However, companies like Match could be reluctant to sell to Facebook after a year's worth of scandals that have damaged Facebook's image and user trust. Regulators might also be reluctant to approve further acquisitions given the company's formidable market power. A Facebook takeover of Match could also turn off online daters who don't trust Facebook with their personal information and might resent a further incursion from the social media giant into their lives.

• [By Demitrios Kalogeropoulos]

  Dating app specialist Match Group (NASDAQ:MTCH) trailed the market last month, falling 13% compared to a 2% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.

• [By Danny Vena]

  There was a lot to like when Match Group (NASDAQ:MTCH) reported its second-quarter financial results on Aug. 7. The company generated revenue of $421 million, up 36% year over year, while operating income jumped 81% compared to the prior-year quarter. Diluted earnings per share of $0.45 soared 165% year over year, as subscriber growth of 27% drove its users past 7.7 million.

• [By Chris Lange]

  Match Group Inc. (NASDAQ: MTCH) is set to release its most recent quarterly results on Tuesday. The consensus forecast calls for $0.23 in EPS and $384.98 million in revenue. Shares traded on Friday's close at $34.82. The consensus price target is $42.56, and the 52-week range is $16.57 to $48.65.

• [By Harsh Chauhan]

  Shares of Match Group (NASDAQ:MTCH) are down this year after delivering impressive gains in 2016, as analysts fear the company's high-growth days might be coming to an end. The Tinder parent's top-line guidance of $1.26 billion to $1.31 billion for the year has raised a red flag, as Wall Street was looking for $1.41 billion in revenue.

Best Penny Stocks To Buy For 2019

tags:RDC,NRG,CPHI,BDL,SIRI,

For investors looking for huge returns with little initial investment, penny stocks are the perfect investment for making triple-digit gains in a matter of days. To help Money Morning readers profit, we're bringing you the three top penny stocks to watch in May 2018.

While many penny stocks have great growth potential, these securities are notoriously volatile and often have little potential for returns.

In order to protect our investments, we follow five rules for investing in penny stocks – take a look at them on the right.

Best Penny Stocks To Buy For 2019: Rowan Companies Inc.(RDC)

Advisors' Opinion:

• [By Logan Wallace]

  Ordocoin (CURRENCY:RDC) traded up 2.1% against the U.S. dollar during the 24 hour period ending at 18:00 PM Eastern on September 22nd. One Ordocoin token can currently be purchased for about $0.0001 or 0.00000001 BTC on exchanges including Crex24, BiteBTC and Stocks.Exchange. In the last seven days, Ordocoin has traded 2.8% higher against the U.S. dollar. Ordocoin has a market cap of $0.00 and approximately $53,260.00 worth of Ordocoin was traded on exchanges in the last 24 hours.

• [By Matthew DiLallo]

  While September was a good month for Ensco, the company made an even bigger splash in October by agreeing to buy fellow offshore driller Rowan (NYSE:RDC) in an all-stock deal. Ensco believes that the combination with Rowan will generate $150 million in annual cost savings while boosting its cash flow per share starting in 2020. It's the company's second major deal since the oil market downturn began; it bought Atwood Oceanics last year for $6.9 billion.

• [By Shane Hupp]

  Rowan Companies (NYSE:RDC) was downgraded by analysts at HSBC Holdings plc from a buy rating to a hold rating.

  Roper Technologies (NYSE:ROP) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating.

• [By Shane Hupp]

  California Public Employees Retirement System reduced its position in Rowan Companies PLC (NYSE:RDC) by 5.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 656,438 shares of the oil and gas company’s stock after selling 41,386 shares during the quarter. California Public Employees Retirement System owned 0.52% of Rowan Companies worth $7,575,000 as of its most recent SEC filing.

Best Penny Stocks To Buy For 2019: NRG Energy Inc.(NRG)

Advisors' Opinion:

• [By Shane Hupp]

  Energi (CURRENCY:NRG) traded 3.8% lower against the dollar during the 24-hour period ending at 22:00 PM Eastern on February 2nd. Energi has a market cap of $9.51 million and approximately $100,521.00 worth of Energi was traded on exchanges in the last day. One Energi coin can currently be bought for approximately $0.76 or 0.00021720 BTC on major cryptocurrency exchanges including CoinExchange, Cryptopia and CryptoBridge. In the last seven days, Energi has traded down 9.3% against the dollar.

• [By Ethan Ryder]

  DTE Energy (NYSE: DTE) and NRG Energy (NYSE:NRG) are both utilities companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

• [By Lee Jackson]

  This stock has made a nice run off the lows, but it may hold solid upside for aggressive accounts. NRG Energy Inc. (NYSE: NRG) is an integrated independent power producer that owns and operates 27 gigawatts (GW) of conventional and renewable generating capacity in the United States and serves 3 million retail customers in Texas and the Northeast.

• [By Shane Hupp]

  State of Wisconsin Investment Board cut its holdings in shares of NRG Energy Inc (NYSE:NRG) by 12.8% in the 2nd quarter, Holdings Channel reports. The firm owned 61,614 shares of the utilities provider’s stock after selling 9,051 shares during the quarter. State of Wisconsin Investment Board’s holdings in NRG Energy were worth $1,892,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

• [By Stephan Byrd]

  Energi (CURRENCY:NRG) traded up 0.2% against the U.S. dollar during the twenty-four hour period ending at 19:00 PM Eastern on September 15th. Over the last seven days, Energi has traded 14.2% higher against the U.S. dollar. Energi has a market capitalization of $1.61 million and $2,597.00 worth of Energi was traded on exchanges in the last 24 hours. One Energi coin can now be purchased for $0.32 or 0.00004969 BTC on exchanges including CoinExchange, Cryptopia and CryptoBridge.

• [By Matthew DiLallo]

  Shares of NRG Energy Inc. (NYSE:NRG) rose 10.9% in August, buoyed by its second-quarter results and an analyst upgrade.

  So what

  "Our business performed exceptionally well during the second quarter," stated CEO Mauricio Gutierrez in the company's earnings press release. Driving that view is that income from continuing operations rose from $99 million in the year-ago period to $121 million in this year's second quarter. Powering the company's improvement was its retail segment, where adjusted EBITDA came in at $298 million, which was $94 million higher than the second quarter of last year. The company's generation business also delivered stronger results as adjusted EBITDA rose $45 million to $197 million. Those dual fuels enabled the company to reaffirm its full-year outlook for adjusted EBITDA between $2.8 billion to $3 billion.

Best Penny Stocks To Buy For 2019: China Pharma Holdings Inc.(CPHI)

Advisors' Opinion:

• [By Logan Wallace]

  These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

  Get Scynexis alerts: Steady Activities: SCYNEXIS, Inc. (NASDAQ:SCYX), LPL Financial Holdings Inc. (NASDAQ:LPLA) (oracleexaminer.com) Do Analysts Think You Should Buy – SCYNEXIS Inc (NASDAQ: SCYX) (stockspen.com) Notable Runner: SCYNEXIS, Inc. (SCYX) (nasdaqplace.com) Most Active Stocks Now: SCYNEXIS, Inc. (NASDAQ:SCYX), China Pharma Holdings, Inc. (NYSE:CPHI), Kala … (journalfinance.net) Overview on price to free cash flow: SCYNEXIS, Inc. (NASDAQ:SCYX), InfuSystem Holdings Inc. (NYSE:INFU) (stocksnewspoint.com)

  Several research analysts have recently issued reports on the company. Roth Capital assumed coverage on Scynexis in a research note on Tuesday, May 8th. They set a “buy” rating and a $6.00 price target for the company. Seaport Global Securities assumed coverage on Scynexis in a research note on Tuesday, April 10th. They set a “buy” rating and a $4.00 price target for the company. Zacks Investment Research raised Scynexis from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, May 8th. HC Wainwright assumed coverage on Scynexis in a research note on Monday, May 7th. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine raised Scynexis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Scynexis currently has an average rating of “Buy” and an average target price of $4.45.

Best Penny Stocks To Buy For 2019: Flanigan's Enterprises Inc.(BDL)

Advisors' Opinion:

• [By Shane Hupp]

  Bitdeal (CURRENCY:BDL) traded 12.6% lower against the dollar during the 24-hour period ending at 15:00 PM ET on July 10th. Bitdeal has a market cap of $592,736.00 and $1,700.00 worth of Bitdeal was traded on exchanges in the last day. One Bitdeal coin can now be bought for $0.0034 or 0.00000053 BTC on popular exchanges including CoinExchange and Cryptopia. During the last seven days, Bitdeal has traded 11.9% lower against the dollar.

• [By Lisa Levin] Gainers Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share. Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million. Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results. Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash. 21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33. Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27. Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating. PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat. NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399. Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643. Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16. Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results. GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results. The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results. Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st
• [By Peter Graham]

  Small cap Flanigan's Enterprises (NYSEAMERICAN: BDL) is considered a "beloved" South Florida institution since 1959 welcoming locals and visitors for over 50 years with a portfolio primarily focused on a collection of family-run restaurants, Flanigan's Seafood Bar And Grill, and retail liquor stores, Big Daddy's Wine and Liquors. As of September 29, 2018, Flanigan's Enterprises (i) operated 26 units consisting of restaurants, package liquor stores and combination restaurants/package liquor stores that the Company either owns or has operational control over and partial ownership in; and (ii) franchised an additional five units, consisting of two restaurants, (one of which they operate) and three combination restaurants/package liquor stores (These figures exclude an adult entertainment club which the Company owned but did not operate and was permanently closed on September 20, 2018 when a Federal Court upheld recently enacted legislation prohibiting the operation of the club as then operated). A Form 10-K noted:

Best Penny Stocks To Buy For 2019: Sirius XM Radio Inc.(SIRI)

Advisors' Opinion:

• [By Rick Munarriz]

  Pandora seemed to be left for dead last summer. Sirius XM Radio (NASDAQ:SIRI) abandoned plans to acquire Pandora, settling for a more cost-effective minority stake in the streaming platform. With Sirius XM content to ride shotgun instead of taking the wheel and listener numbers languishing, investors started dumping the stock through the latter half of last year.  

• [By Jeremy Bowman]

  Shares of Sirius XM Holdings (NASDAQ:SIRI) took a spill in September as investors gave a thumbs-down to its acquisition of Pandora Media (NYSE:P). According to data from S&P Global Market Intelligence, shares of the satellite radio service finished last month down 11%. As you can see from the chart below, most of the sell-off came as it announced its takeover of Pandora toward the end of the month.

• [By Rick Munarriz]

  Shares of Sirius XM Holdings (NASDAQ:SIRI) hit another 12-year high on Monday. The country's lone satellite radio provider would go on to improve its fundamentals, announcing that it's laying to rest a pending legal matter by settling with SoundExchange.

• [By Rick Munarriz]

  Sirius XM Holdings (NASDAQ:SIRI) is gearing up for a big earnings announcement this week. The satellite radio provider reports first-quarter results before Wednesday's market open, and a lot is riding on its financial performance. Sirius XM has been one of the market's biggest winners since bottoming out at $0.05 -- yes, a nickel -- in 2009. The stock is now a 127-bagger, and it hit a new 12-year high just last month.